The overall goal of this NIS is to document and compare long-term outcomes of subjects
receiving ADVATE or ADYNOVI in routine clinical practice, in terms of quality of life,
hemophilia-related co-morbidity, drug utilization, effectiveness and safety.
Primary Objective:
To determine joint health outcome in subjects receiving ADVATE or ADYNOVI
Secondary Objectives:
To determine quality of life in subjects receiving ADVATE or ADYNOVI
To determine hemostatic effectiveness of ADVATE and ADYNOVI in a variety of
clinical settings including on demand therapy, routine standardized prophylaxis, and
individual pharmacokinetic (PK) –guided prophylactic therapy
To determine hemophilia related co-morbidity
To determine drug utilization of subjects receiving ADVATE or ADYNOVI
To determine safety and immunogenicity of ADVATE and ADYNOVI